AstraZeneca may have provided an incomplete view of the efficacy data related to its COVID-19 vaccine clinical trial, according to the National Institute of Allergy and Infectious Diseases (NIAID) on Tuesday.

AstraZeneca may have provided an incomplete view of the efficacy data related to its COVID-19 vaccine clinical trial, according to the National Institute of Allergy and Infectious Diseases (NIAID) on Tuesday.